BusinessaTyr Pharma Presents Analyses of Resolaris Phase 1b/2 Trial in Patients with Limb Girdle Muscular Dystrophy 2B and Facioscapulohumeral Muscular Dystrophy at the American Academy of Neurology 69th Annual MeetingBy Nasdaq OMXApr 24, 2017, 12:02 PM UTC
BusinessaTyr Pharma Presents Analyses of Resolaris Phase 1b/2 Trial in Patients with Limb Girdle Muscular Dystrophy 2B and Facioscapulohumeral Muscular Dystrophy at the American Academy of Neurology 69th Annual MeetingBy Nasdaq OMXApr 24, 2017, 12:02 PM UTC
BusinessaTyr Pharma Announces Promising Top-Line Results from Resolaris™ Phase 1b/2 Clinical Trial in Patients with Early Onset Facioscapulohumeral Muscular DystrophyBy Nasdaq OMXApr 24, 2017, 11:30 AM UTC
BusinessaTyr Pharma Announces Appointment of Timothy P. Coughlin to its Board of DirectorsBy Nasdaq OMXApr 10, 2017, 9:00 PM UTC
BusinessaTyr Pharma to Present at Needham and Company 16th Annual Healthcare ConferenceBy Nasdaq OMXMar 29, 2017, 1:02 PM UTC
BusinessaTyr Pharma to Present at Needham and Company 16th Annual Healthcare ConferenceBy Nasdaq OMXMar 29, 2017, 1:02 PM UTC
BusinessaTyr Pharma to Present at Needham and Company 16th Annual Healthcare ConferenceBy Nasdaq OMXMar 29, 2017, 1:02 PM UTC
